Table 1 of
Gnanasekaran, Mol Vis 2020; 26:246-256. Table 1 of
Gnanasekaran, Mol Vis 2020; 26:246-256.
Table 1. Baseline clinical characteristics of the patients with diabetic macular edema.
| Characteristic | Values |
|---|---|
| Number of patients | 25 |
| Gender, male/ female (%) | 18/7 (72.0/ 28.0) |
| Mean age of patients, years, mean (±SD) | 63.8 (9.5) |
| Glycated hemoglobin, %, mean (±SD) | 7.54 (1.19) |
| Treatment | |
| Oral hypoglycaemic agent, n (%) | 10 (40.0) |
| Insulin, n (%) | 1 (4.0) |
| Oral hypoglycaemic agent plus insulin, n (%) | 14 (56.0) |
| Hypertension, n (%) | 19 (76.0) |
| Dyslipidaemia, n (%) | 23 (92.0) |
| Duration of diabetes | |
| <5 years, n (%) | 4 (13.3) |
| 5 to 10 years, n (%) | 4 (13.3) |
| 10 to 15 years, n (%) | 5 (16.7) |
| >15 years, n (%) | 17 (56.7) |
| BCVA (logMAR), median (IQR) | 61.5 (55 – 67) |
| CMT, µm (mean ± SD) | 484.5 (134.3) |
| Phakic lens status, n (%) | 21 (84.0) |
| Stage of diabetic retinopathy, n (%) | |
| Mild NPDR | 0 (0.0) |
| Moderate NPDR | 13 (52.0) |
| Severe NPDR | 10 (40.0) |
| Proliferative DR | 2 (8.0) |
| History of focal photocoagulation, n (%) | 8 (32.0) |
| History of panretinal photocoagulation, n (%) | 6 (24.0) |
| History of intravitreal anti-VEGF, n (%) | 7 (28.0) |
| History of intravitreal corticosteroids, n (%) | 1 (4) |